Spotlight Pathology, a UK-based healthtech startup, has secured £1.4 million in funding to accelerate the development and clinical validation of its AI-powered platform for early detection of blood cancers. The capital will support expansion of its digital pathology tools, refinement of machine learning models for leukaemia and lymphoma detection, and preparation for regulatory submissions and larger-scale clinical studies.
Glimpse:
The funding round will enable Spotlight Pathology to enhance its AI algorithms that analyse blood smears, bone marrow biopsies, and flow cytometry data to identify malignant cells with higher accuracy and speed than traditional manual methods. The platform aims to reduce diagnostic delays, improve subclassification of blood cancers, and support pathologists in high-volume or resource-limited settings. The company plans to use the funds for further clinical validation, team expansion, and initial commercial pilots in the UK and select European markets.
Spotlight Pathology, a London-based startup developing AI solutions for digital pathology, has successfully raised £1.4 million to advance its platform focused on the early and accurate detection of blood cancers. The funding round, closed on February 27, 2026, was supported by a mix of venture investors and healthtech-focused angels who see strong potential in applying artificial intelligence to haematopathology, a field where timely and precise diagnosis can dramatically improve patient outcomes.
The company’s core technology uses advanced computer vision and deep learning models to analyse digital images of peripheral blood smears, bone marrow aspirates, and biopsy slides. The AI system is trained to detect subtle morphological changes indicative of leukaemia, lymphoma, and other haematological malignancies, while also assisting in subclassification and risk stratification. By automating parts of the labour-intensive manual review process, Spotlight Pathology aims to reduce diagnostic turnaround times, minimize inter-observer variability, and help pathologists manage increasing caseloads more efficiently.
The new capital will be used to expand the development team, refine the AI models with larger and more diverse datasets (including rare subtypes), conduct additional multi-centre clinical validation studies, and prepare for regulatory pathways in the UK and Europe. The company is also planning initial commercial pilots with leading haematology centres to demonstrate real-world impact on diagnostic accuracy and workflow efficiency.
Blood cancers remain a significant global health challenge, with early detection often hindered by the complexity of morphological interpretation and limited specialist availability. Spotlight Pathology’s AI platform addresses these pain points by providing consistent, high-sensitivity assistance to pathologists, potentially leading to earlier treatment initiation and better survival rates. The startup joins a growing wave of AI companies targeting pathology, where digital transformation is creating new opportunities to improve cancer diagnostics at scale.
This funding round underscores continued investor confidence in AI applications for oncology and diagnostics, particularly in areas where traditional methods are time-consuming and highly dependent on specialist expertise. Spotlight Pathology is now well-positioned to move from development toward clinical adoption, with ambitions to expand its platform to other cancer types in the future.
“Blood cancer diagnosis is complex and time-sensitive. Our AI tools are designed to support pathologists with faster, more consistent insights so patients can receive the right treatment as early as possible.”
By
HB Team
Related News
